Merck & Co. lost the second trial to reach a verdict over claims its osteoporosis drug Fosamax causes so-called jaw death. The jury set damages at $8 million.
A jury in New York ruled against Merck today in the case of Shirley Boles, 72, of Fort Walton Beach, Florida. Boles claimed she developed osteonecrosis of the jaw, or ONJ, from taking Fosamax. The first Fosamax case resulted in a Merck victory in May.
Recently a link has been found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw (ONJ aka. Dead Jaw). This important discovery clearly shows that Fosamax side effects may include osteonecrosis of the jaw, aka, dead jaw or jaw death as well as osteomyelitis of the jaw. Fosamax has also been linked to low energy femur fractures (thigh bone fractures).
The case is Boles v. Merck & Co., 06-cv-09455, and the lawsuits are combined in In Re Fosamax Products Liability Litigation, MDL 1789, U.S. District Court, Southern District of New York (Manhattan).
Read full Bloomberg story here.
Continue reading